Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Varenicline on Smoking Cessation in Patients With Schizophrenia: Evaluation of Antipsychotic Drug-Induced Neurological Symptoms as Correlates of Response

NCT03495024 is registered in ClinicalTrials.gov with Corporal Michael J. Crescenz VA Medical Center as lead sponsor.

NCT NCT03495024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03495024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Varenicline on Smoking Cessation in Patients With Schizophrenia: Evaluation of Antipsychotic Drug-Induced Neurological Symptoms as Correlates of Response
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Phase
Phase 4
Overall status
Recruiting
Start date
January 1, 2019
Completion date
June 30, 2020
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinsonism, schizoaffective disorder, schizophrenia, tardive dyskinesia, tobacco smoking